I'd rather have a slow couple of months for RVX than get the bombshell of ESPR market response that Esperion just received following their Clinical Development and Regulatory Update yesterday. If a waffling by the FDA, with clear green light go endorsement from EMA, for bempedoic acid elicits a near 40% drop in ESPR share price, I wonder how the market would respond to FDA clarity for RVX-208 in BETonMACE?

BearDownAZ